Clinical Trial Update: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trials evaluating elironrasib and daraxonrasib as solo therapies and in combination for advanced KRAS G12C-mutant solid tumors, curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Daraxonrasib
• Elironrasib

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING